Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell Lymphoma Treated with Crizotinib

The prognosis of the primary refractory anaplastic lymphoma kinase (ALK+) anaplastic T large cell lymphoma is ominous. The identification of molecular targets with potential to drive oncogenesis remains a cornerstone for the designing of new selective cancer therapies. Crizotinib is a selective ATP-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rare Tumors
Main Authors: Mahuad, Carolina Valeria, Repáraz, María de los Ángeles Vicente, Zerga, Marta E., Aizpurua, María Florencia, Casali, Claudia, Garate, Gonzalo
Formato: Artigo
Idioma:Inglês
Publicado em: PAGEPress Publications, Pavia, Italy 2016
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4935828/
https://ncbi.nlm.nih.gov/pubmed/27441079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4081/rt.2016.6266
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados